Neutralizing responses in fully vaccinated with BNT162b2, CoronaVac, ChAdOx1, and Ad26.COV2.S against SARS-CoV-2 lineages in Colombia, 2020-2021
Authors:
- Diego A. Álvarez-DíazDÁDiego A. Álvarez-Díaz
- Ana Luisa MuñozAMAna Luisa Muñoz
- María T. Herrera-SepúlvedaMHMaría T. Herrera-Sepúlveda
- Pilar Tavera-RodríguezPTPilar Tavera-Rodríguez
- Katherine Laiton-DonatoKLKatherine Laiton-Donato
- Carlos Franco-MuñozCFCarlos Franco-Muñoz
- Héctor Alejandro Ruiz-MorenoHRHéctor Alejandro Ruiz-Moreno
- Dioselina Pelaez-CarvajalDPDioselina Pelaez-Carvajal
- Alejandra M. Muñoz-SuarezAMAlejandra M. Muñoz-Suarez
- Jhonnatan Reales-GonzalezJRJhonnatan Reales-Gonzalez
- Jenssy D. CatamaJCJenssy D. Catama
Preprint
Abstract
Background By March 2022, around 34 million people in Colombia had received a complete scheme of vaccines against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) including, mRNA-based vaccines, viral vectored coronavirus vaccines, or the inactivated whole virus vaccine. However, as several SARS-CoV-2 variants of concern (VOC) and interest (VOI) co-circulate in the country, determining the resistance level to vaccine-elicited neutralizing antibodies (nAbs) is useful to improve the efficacy of COVID-19 vaccination programs. Methods Microneutralization assays with the most prevalent SARS-CoV-2 lineages in Colombia during 2020-2021 were performed using serum samples from immunologically naïve individuals between 9 and 13 weeks after receiving complete regimens of CoronaVac, BNT162b2, ChAdOx1, or Ad26.COV2.S. The mean neutralization titer (MN50) was calculated by the Reed–Muench method and used to determine differences in vaccine-elicited nAbs against the SARS-CoV-2 lineages B.1.111, P.1 (Gamma), B.1.621 (Mu), and AY.25.1 (Delta). Results The most administered vaccines in the country, BNT162b2 and CoronaVac, elicited significantly different nAb responses against Mu, as the GMTs were 75.7 and 5.9-fold lower relative to the control lineage (B.1.111), while for Delta were 15.8 and 1.1-fold lower, respectively. In contrast, nAb responses against Mu and Delta were comparable between ChAd0×1-s and Ad26.COV2.S as the GMTs remained around 5 to 7-fold lower relative to B.1.111. Conclusions The emergence of SARS-CoV-2 variants in Colombia with a significant capacity to escape from vaccine-elicited nAbs indicates that a booster dose is highly recommended. Furthermore, other non-pharmacological measures should be retained in the vaccinated population.Keywords
This publication has 21 references indexed in Scilit:
- High-titer neutralization of Mu and C.1.2 SARS-CoV-2 variants by vaccine-elicited antibodies of previously infected individualsCell Reports, 2021
- Reduced levels of convalescent neutralizing antibodies against SARS-CoV-2 B.1+L249S+E484K lineageVirus Research, 2021
- Characterization of the emerging B.1.621 variant of interest of SARS-CoV-2Infection, Genetics and Evolution, 2021
- Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative reviewClinical Microbiology and Infection, 2021
- Neutralisation of SARS-CoV-2 lineage P.1 by antibodies elicited through natural SARS-CoV-2 infection or vaccination with an inactivated SARS-CoV-2 vaccine: an immunological studyThe Lancet Microbe, 2021
- Resistance of SARS-CoV-2 Delta variant to neutralization by BNT162b2-elicited antibodies in AsiansThe Lancet Regional Health - Western Pacific, 2021
- Infection and Vaccine-Induced Neutralizing-Antibody Responses to the SARS-CoV-2 B.1.617 VariantsNew England Journal of Medicine, 2021
- Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infectionNature Communications, 2021
- Antibody evasion by the P.1 strain of SARS-CoV-2Cell, 2021
- Neutralizing antibody titres in SARS-CoV-2 infectionsNature Communications, 2021